Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Open-label Study Investigating the Excretion Balance, Pharmacokinetics, and Metabolism of a Single Oral Dose of [14C/12C]-Labeled Fenebrutinib in Healthy Volunteers

Trial Profile

A Phase 1 Open-label Study Investigating the Excretion Balance, Pharmacokinetics, and Metabolism of a Single Oral Dose of [14C/12C]-Labeled Fenebrutinib in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Oct 2018

At a glance

  • Drugs Fenebrutinib (Primary)
  • Indications Autoimmune disorders; Rheumatoid arthritis; Systemic lupus erythematosus; Urticaria
  • Focus Adverse reactions
  • Sponsors Genentech; Roche
  • Most Recent Events

    • 25 Sep 2018 Status changed from recruiting to completed.
    • 30 Jul 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top